Addressing IOP and QOL With LAL, iStent, and Dextenza

Show Description +

I. Paul Singh, MD, discusses the current technologies available to maintain good quality of life (QOL) for patients while also aggressively managing IOP. In this case, the patient had a history of primary open-angle glaucoma and monovision. Dr. Singh demonstrates the implantation of an Light Adjustable Lens (LAL, RxSight) and iStent (Glaukos) with use of Dextenza (dexamethasone ophthalmic insert 0.4 mg, Ocular Therapeutix).

Posted: 2/27/2023

Addressing IOP and QOL With LAL, iStent, and Dextenza

I. Paul Singh, MD, discusses the current technologies available to maintain good quality of life (QOL) for patients while also aggressively managing IOP. In this case, the patient had a history of primary open-angle glaucoma and monovision. Dr. Singh demonstrates the implantation of an Light Adjustable Lens (LAL, RxSight) and iStent (Glaukos) with use of Dextenza (dexamethasone ophthalmic insert 0.4 mg, Ocular Therapeutix).

Posted: 2/27/2023

Please log in to leave a comment.

More in Glaucoma

Achieving Success in Interventional Glaucoma

Iqbal Ike K. Ahmed, MD, FRCSC; John Berdahl, MD; Savak Teymoorian, MD, MBA; and Mitch Ibach, OD, FAAO

Collaborative Care in Interventional Glaucoma

Iqbal Ike K. Ahmed, MD, FRCSC; John Berdahl, MD; Savak Teymoorian, MD, MBA; and Mitch Ibach, OD, FAAO

What Does It Mean to Be Interventional?

Iqbal Ike K. Ahmed, MD, FRCSC; John Berdahl, MD; Savak Teymoorian, MD, MBA; and Mitch Ibach, OD, FAAO